Here is an odd idea about aging muscle: the repair signal may not be running out. It may be getting chemically damaged before it can deliver its message.
That is the premise behind research from Kyushu University in Japan, where scientists found that a sulfur-containing molecule called lipoic acid trisulfide, or LASSS, can interact with hepatocyte growth factor (HGF), a protein involved in activating muscle stem cells, and more than double its measured binding to a key receptor under laboratory conditions.
The researchers call the enhanced form “Super HGF.” They also found that LASSS protected the protein against a chemical modification associated with aging, while experiments in cultured muscle stem cells supported the biological mechanism. In a small mouse experiment, the compound reduced HGF nitration during temporary muscle disuse.
That is interesting chemistry. It is not yet a muscle-repair treatment. The researchers did not demonstrate improved strength, restored muscle mass or faster regeneration in humans, and no human participants were treated with LASSS.
The paper was published in Scientific Reports on July 24, 2026, with a university announcement the same day. ScienceDaily carried a later account on November 4, bringing the findings renewed attention.
What makes the discovery worth examining is not an immediate therapeutic promise. It is the possibility that aging muscle may lose some regenerative capacity because an existing biological signal becomes chemically disabled rather than simply disappearing.
What Hepatocyte Growth Factor Does in Aging Muscle
Despite its name, hepatocyte growth factor is not exclusively concerned with the liver.
HGF participates in development, regeneration and repair across several tissues. In skeletal muscle, one of its important functions is activating satellite cells, the resident stem cells that help maintain and repair muscle fibers.
These cells normally remain relatively inactive between the muscle fiber membrane and its surrounding basal lamina. When muscle is injured or mechanically stimulated, they can enter the cell cycle, proliferate and contribute to regeneration.
HGF helps initiate that process by binding to a cell-surface receptor called c-Met.
The interaction acts as a biological activation signal. Without effective communication between HGF and c-Met, part of the cellular response needed for muscle maintenance and repair can become impaired.
Ryuichi Tatsumi’s research group at Kyushu University has investigated this pathway for years, particularly its relationship to mechanical stimulation, satellite-cell activity and aging.
Earlier work from the group showed that HGF undergoes a chemical modification called tyrosine nitration in aging muscle.
Nitration occurs when reactive nitrogen species, including peroxynitrite, modify particular amino acids within a protein. In the case of HGF, the researchers identified two important tyrosine residues, Y198 and Y250, located in regions involved in receptor binding.
The modification can interfere with the protein’s interaction with c-Met, weakening its ability to activate muscle satellite cells.
The group’s previous experiments associated this process particularly with fast-twitch muscle fibers, which are important for rapid, powerful movements and can be disproportionately affected during aging.
That leads to a different way of thinking about muscle deterioration.
Instead of assuming that older muscle simply lacks sufficient repair signals, it raises the possibility that some signals remain present but have lost part of their biological activity.
Tatsumi summarized the underlying idea in Kyushu University’s announcement: “HGF is not necessarily missing as we age.”
The rust analogy is useful, although it is not chemically literal. Protein nitration is not the same reaction as iron corrosion. What connects them is the loss of function caused by chemical alteration of material that remains physically present.
Importantly, this does not mean HGF nitration explains every aspect of age-related muscle loss. Sarcopenia involves multiple biological processes, including changes in nerve function, muscle protein turnover, inflammation and the cellular environment surrounding muscle fibers.
The Kyushu study examines one potential contributor to that much larger problem.
The signal may still be present. The question is whether aging has changed the protein enough to prevent its message from getting through.
The Sulfur Molecule That Strengthened HGF’s Receptor Binding
The researchers investigated two sulfur-rich molecules belonging to a chemical class called trisulfides.
Trisulfides contain three consecutively linked sulfur atoms and can participate in chemical reactions involving oxidative and nitrosative stress.
The team tested glutathione trisulfide, abbreviated GSSSG, and lipoic acid trisulfide, abbreviated LASSS, to determine whether either could protect HGF from nitration.
In the initial laboratory experiments, both compounds reduced nitration at the two vulnerable tyrosine sites, Y198 and Y250.
That suggested an ability to protect HGF against chemical damage under the experimental conditions.
But the more surprising result appeared when the researchers increased the experimental ratio of the trisulfides to HGF.
At an HGF-to-LASSS molar ratio of 1:8000, LASSS-treated HGF displayed more than twice the receptor-binding signal measured for untreated HGF in the researchers’ biochemical assay.
That measurement concerns the interaction between HGF and c-Met under controlled laboratory conditions. It does not mean muscle regeneration doubled or that a clinical treatment would be twice as effective.
The team then used ultrafiltration to remove unreacted LASSS before testing receptor binding again.
The enhanced interaction persisted after the removal of free compound.
That finding was important because it suggested that LASSS was doing more than temporarily neutralizing reactive molecules in the surrounding solution.
The researchers proposed that LASSS may interact directly with HGF and produce a chemical modification affecting the protein’s structure or behavior.
The precise modification remains unknown. The study did not directly identify which molecular bonds changed or establish a three-dimensional structure for the proposed enhanced HGF form.
The controls helped establish that the effect was chemically specific.
Glutathione trisulfide protected HGF against nitration in earlier experiments but did not reproduce LASSS’s pronounced enhancement of receptor binding.
Ordinary lipoic acid, which contains a disulfide rather than the trisulfide structure of LASSS, also failed to produce the same binding-enhancing and nitration-resistant effects in the relevant experiments.
That is an important distinction because lipoic acid is widely sold as a dietary supplement.
The commercially familiar substance is not interchangeable with LASSS. The findings provide no evidence that taking ordinary lipoic acid supplements strengthens HGF signaling or prevents age-related muscle loss.
The 1:8000 molar ratio is likewise a laboratory experimental condition. It is not a proposed human dose, and the study establishes no supplementation regimen.
The important finding is not that sulfur in general improves muscle repair. It is that one particular trisulfide produced an effect that closely related compounds did not reproduce.
What the Cultured Muscle Cells and Mouse Experiments Showed
The researchers did not stop at measuring the interaction between purified HGF and its receptor.
They also tested whether chemically protected HGF could retain biological activity in primary cultures of muscle satellite cells isolated from rats.
In these experiments, untreated HGF helped activate the cultured satellite cells, while exposure to nitrating conditions reduced its ability to do so.
When HGF was pretreated with LASSS or glutathione trisulfide under specified conditions, much of that activity was preserved after exposure to peroxynitrite.
The team measured cellular activation using bromodeoxyuridine incorporation, a laboratory indicator of cells entering DNA synthesis and the cell cycle.
Additional experiments found that LASSS-treated HGF could produce strong satellite-cell activation even at a lower HGF concentration than untreated control preparations.
Those findings provide a functional connection between the biochemical observations and the cellular signaling pathway involved in muscle repair.
But cultured-cell activation is still not the same as demonstrating that a damaged muscle regenerates faster in a living organism.
The researchers next examined whether LASSS could protect HGF against nitration in living mice.
They used a tail-suspension model in which the animals’ hind limbs are unloaded for several days. This produces changes associated with muscle inactivity and is commonly used in studies of disuse atrophy.
The experiment involved young male mice approximately eight weeks old, divided into four groups with about three animals per group.
One group served as the untreated control. Another underwent five days of tail suspension. The remaining groups received LASSS or glutathione trisulfide for three days before the five-day unloading period.
The compounds were not continued during the suspension period.
When the researchers examined muscle tissue, they found that LASSS pretreatment prevented the increase in HGF nitration seen in the disuse group.
Glutathione trisulfide did not reproduce that protective effect in the mouse experiment.
That is useful evidence that the biochemical mechanism may operate in living tissue, not only in purified-protein experiments.
It is also a very limited animal experiment.
The number of animals was small, the mice were young rather than aged, and the unloading period lasted only five days.
The researchers reported a trend toward reduced soleus muscle weight with disuse, but did not demonstrate that LASSS preserved muscle mass or reversed atrophy.
They did not report improved muscle strength, walking performance or faster regeneration after injury.
The mouse findings therefore support a molecular mechanism: LASSS can reduce HGF nitration under an experimental disuse condition.
They do not establish that LASSS prevents sarcopenia, improves physical function or works as an anti-aging treatment.
Protecting a repair signal from chemical damage is not the same as proving that a muscle became stronger or regenerated faster.
Why This Muscle-Repair Research Matters Beyond the Lab
The significance of this research lies in its proposed mechanism, not in any immediate application to patients.
Maintaining muscle mass, strength and regenerative capacity becomes increasingly important with age.
Sarcopenia, the progressive loss of muscle strength and quantity associated with aging, can interfere with mobility, physical independence and recovery from illness or injury.
Researchers are investigating multiple ways to preserve muscle function, including approaches targeting muscle protein metabolism, inflammation, stem-cell activity and signaling pathways that regulate muscle growth.
The Kyushu work adds a different question: can an existing repair signal be protected from chemical dysfunction rather than replaced or produced in greater quantities?
That approach has an interesting parallel with current research into preserving muscle during pharmaceutical weight loss.
Some investigational treatments aim to limit muscle loss by targeting myostatin and activin signaling, biological pathways involved in regulating muscle growth.
Grey Pepper has explored those approaches in its reporting on trevogrumab and muscle loss during obesity-drug treatment, as well as in its analysis of higher-quality weight loss and muscle preservation.
The Kyushu study examines a different part of muscle biology.
Instead of reducing a signal that restricts muscle growth, it investigates whether chemical damage to an activating signal interferes with the cellular process involved in repair.
That does not mean LASSS has been shown to protect muscle during GLP-1 treatment. The researchers did not study obesity medicines, drug-induced weight loss or changes in human body composition.
The connection is conceptual: different molecular pathways may eventually be useful for addressing different aspects of muscle deterioration.
There are also reasons to approach HGF enhancement cautiously.
HGF and c-Met participate in signaling beyond skeletal muscle, including processes associated with tissue growth, development and repair.
The pathway is also extensively investigated in oncology because abnormal c-Met signaling can contribute to cancer progression in some settings.
That does not mean LASSS was shown to cause cancer. The study was not designed to evaluate cancer risk, and no such conclusion can be drawn from its results.
It does mean that any future therapy intended to enhance HGF signaling would need careful investigation of where the effect occurs, how long it persists and whether it creates unwanted activity in other tissues.
The researchers themselves identify the need for further experiments involving aged animals, safety and functional outcomes.
For now, this remains an early study of protein chemistry and muscle-cell signaling rather than an intervention ready for clinical use.
What Needs to Happen Before Super HGF Becomes a Treatment
The next experiments are reasonably clear.
First, researchers need to establish whether LASSS produces meaningful biological benefits in genuinely aged animals.
Young mice temporarily suspended by their tails can model a specific form of muscle disuse, but they cannot reproduce the decades of molecular, neurological and metabolic changes involved in human aging.
Aged-animal studies could test whether protecting HGF from nitration preserves muscle stem-cell function, reduces fibrosis or improves regenerative responses after injury.
Second, experiments need to measure actual muscle outcomes.
These could include muscle mass, fiber size, contractile strength, recovery after injury and functional performance.
Without such measurements, improvements in receptor-binding activity remain mechanistic findings rather than demonstrations of therapeutic benefit.
Third, the chemical mechanism requires clarification.
The investigators have proposed that LASSS may alter particular disulfide bonds within HGF, creating small structural changes that improve receptor binding and protect vulnerable tyrosine residues.
That is a plausible working model, but the paper did not directly identify the modified bonds or establish the proposed structural changes.
Studies that map the chemical interaction and protein structure would help determine whether the enhanced activity results from a reproducible, identifiable molecular modification.
Fourth, longer-term safety testing is necessary.
Because the HGF–c-Met pathway operates in several biological systems, researchers need to determine whether the desired muscle-related effects can be achieved without unwanted signaling elsewhere.
Only after substantial preclinical work could human studies reasonably begin to address safety, appropriate exposure and possible clinical benefits.
There is currently no established LASSS treatment for sarcopenia or muscle regeneration, and the findings do not support using ordinary lipoic acid supplements for that purpose.
Those limitations should not obscure the scientific contribution.
The researchers demonstrated that HGF’s interaction with its receptor can be enhanced under specific laboratory conditions, and that the same compound can protect HGF from nitration in a small mouse experiment.
The combination suggests a new direction for investigating how chemically damaged growth factors might be protected or restored.
That is a meaningful starting point. It is not yet evidence of a therapy.
A Small Study With a Bigger Question About Aging
The most interesting part of the Super HGF research is its change in perspective.
Aging is often described as a process in which useful biological components become depleted: fewer functioning cells, weaker growth signals and declining capacity for repair.
Sometimes that is true. But this study points toward another possibility in one specific pathway.
A biological signal may still be available while chemical modification prevents it from functioning normally.
If researchers can identify how that modification occurs and how to prevent it safely, preserving existing proteins might become one component of future regenerative strategies.
That possibility remains speculative in terms of treating sarcopenia. The current results are from protein-binding experiments, cultured rat muscle satellite cells and a small disuse experiment in young mice.
There is no evidence yet that LASSS restores strength to aging humans, prevents mobility decline or provides a clinically meaningful improvement in muscle regeneration.
Nor is there evidence that a commercially available lipoic acid supplement can reproduce the effect.
The distinction matters because laboratory discoveries involving familiar-sounding chemicals can easily be transformed into consumer claims before the evidence warrants them.
What the Kyushu research actually demonstrates is more specific, and more interesting scientifically: a particular sulfur-containing compound altered the measured behavior of a muscle-repair protein in ways that closely related compounds did not.
The researchers now have a hypothesis they can test in older animals and eventually, if justified by efficacy and safety results, in people.
For the moment, Super HGF is not a treatment but a useful scientific question.
What if part of aging muscle’s problem is not that its repair signal has disappeared, but that the signal has been chemically damaged before it can be heard?
Sources and Further Reading
- Zushi K, Seki M, Mizuochi R, et al. Enhanced HGF With Increased Receptor Affinity and Nitration-Dysfunction Resistance Through Interaction With Lipoic Acid Trisulfide. Scientific Reports, July 24, 2026.
- PubMed Central: Full-Text Scientific Reports Study, Including Biochemical Assays, Satellite-Cell Experiments and Mouse Methods.
- Kyushu University: Scientists Find Compound That May Help Muscles Stay Strong as We Age, July 24, 2026.
- ScienceDaily / Kyushu University: A Surprising Discovery Could Help Aging Muscles Repair Themselves, November 4, 2026.
- Elgaabari A, et al. Age-Related Nitration/Dysfunction of Myogenic Stem Cell Activator HGF. Aging Cell, 2024.
